Built from Helus Pharma Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$8.86-5.6%Nov 12 close
Reported results on November 12, 2026; they are not in these figures yet.
Figures through March 31, 2026, from the 40-F filed June 29, 2026
The themes Helus Pharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.5BA+
EXELExelixis, Inc.$17BA+
JAZZJazz Pharmaceuticals plc$15.4BA
HALOHalozyme Therapeutics, Inc.$11.5BA+
TECHBIO-Techne Corp$11.4BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now ANot rated
The band under the price shows the grade on each date, built only from filings that were public by then.
There is no grade history to chart for Helus Pharma Inc. yet. The quarterly grade is rebuilt from only the filings that were public at the time, and this company has not yet reported enough of them to score a single quarter.